XML 48 R40.htm IDEA: XBRL DOCUMENT
v3.23.2

Acquisitions and divestitures - Narrative: Proposed Acquisition of Horizon Therapeutics plc (Details) $ / shares in Units, $ in Billions | 6 Months Ended |
--- | --- | ---
Jun. 30, 2023 USD ($) | Dec. 12, 2022 program product $ / shares
Business Acquisition [Line Items] |  |
Cash payment | $ 27.8 |
Horizon Therapeutics |  |
Business Acquisition [Line Items] |  |
Business acquisition, share price (in dollars per share) | $ / shares |  | $ 116.50
Cash payment | $ 27.8 |
Approved products | product |  | 12
Development programs | program |  | 20

X
- Definition Approved products + References No definition available. + Details
Name: | amgn_ApprovedProducts
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Development programs + References No definition available. + Details
Name: | amgn_DevelopmentPrograms
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |